Article info
PDFClinical and epidemiological research
Concise report
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
- Correspondence to Professor Arthur Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, La Jolla, California 92093, USA; akavanaugh{at}ucsd.edu
Citation
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
Publication history
- Received May 31, 2017
- Revised October 30, 2017
- Accepted November 3, 2017
- First published November 16, 2017.
Online issue publication
January 12, 2018
Article Versions
- Previous version (16 November 2017).
- Previous version (4 December 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/